The efficacy of self-assembled cationic antimicrobial peptide nanoparticles against Cryptococcus neoformans for the treatment of meningitis

Biomaterials

Volumn 31, Issue 10, 2010, Pages 2874-2881

  Wang, Huaying ^a   Xu, Kaijin ^a   Liu, Lihong ^b   Tan, Jeremy P K ^b   Chen, Yunbo ^a   Li, Yongtao ^a   Fan, Weimin ^a,c   Wei, Zeqing ^a   Sheng, Jifang ^a   Yang, Yi Yan ^b   Li, Lanjuan ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b INSTITUTE OF BIOENGINEERING AND NANOTECHNOLOGY   (Singapore)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Antimicrobial peptide; Blood brain barrier (BBB); Cationic nanoparticles; Cryptococcus neoformans; Meningitis

Indexed keywords

AMPHOTERICIN B; ANTI-MICROBIAL ACTIVITY; ANTI-MICROBIAL AGENT; ANTIFUNGAL AGENTS; ANTIMICROBIAL PEPTIDE; BIODISTRIBUTIONS; BLOOD-BRAIN BARRIER; BRAIN TISSUE; CATIONIC ANTIMICROBIAL PEPTIDES; CATIONIC NANOPARTICLES; CELL WALLS; CLINICAL ISOLATES; CRYPTOCOCCUS NEOFORMANS; FLUCONAZOLE; IN-VITRO; KIDNEY FUNCTION; MINIMUM INHIBITORY CONCENTRATION; NEOFORMANS; RABBIT MODELS; SELF-ASSEMBLED; TEM; YEAST GROWTH;

BLOOD; PEPTIDES; POLYPEPTIDES; YEAST;

NANOPARTICLES;

AMPHOTERICIN B; ANTIMICROBIAL CATIONIC PEPTIDE; CHOLESTEROL; FLUCONAZOLE; NANOPARTICLE; TRANSACTIVATOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFUNGAL ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; CELL DAMAGE; CELL WALL; CONTROLLED STUDY; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCUS NEOFORMANS; CYTOPLASM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG PENETRATION; ELECTROLYTE DISTURBANCE; EXPERIMENTAL RABBIT; FUNGUS GROWTH; FUNGUS ISOLATION; GROWTH INHIBITION; LIVER TOXICITY; MINIMUM INHIBITORY CONCENTRATION; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; COLONY COUNT, MICROBIAL; CRYPTOCOCCUS NEOFORMANS; DISEASE MODELS, ANIMAL; FLUCONAZOLE; FLUORESCEIN-5-ISOTHIOCYANATE; MENINGITIS, CRYPTOCOCCAL; MOLECULAR SEQUENCE DATA; NANOPARTICLES; RABBITS; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

FILOBASIDIELLA NEOFORMANS; ORYCTOLAGUS CUNICULUS;

EID: 75149139976     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2009.12.042     Document Type: Article

References (34)

1. Pukkila-Worley R., and Mylonakis E. Epidemiology and management of cryptococcal meningitis: developments and challenges. Expert Opin Pharmacother 9 (2008) 551-560
2. Saag M.S., Graybill R.J., Larsen R.A., Pappas P.G., Perfect J.R., Powderly W.G., et al. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis 30 (2000) 710-718
3. Gallis H.A., Drew R.H., and Pickard W.W. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 12 (1990) 308-329
4. Zhang X.B., Xie J.X., Li S., Wang X.T., and Hou X.P. The study on brain targeting of the amphotericin B liposomes. J Drug Target 11 (2003) 117-122
5. Groll A.H., Piscitelli S.C., and Walsh T.J. Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Adv Pharmacol 44 (1998) 343-500
6. Sar B., Monchy D., Vann M., Keo C., Sarthou J.L., and Buisson Y. Increasing in vitro resistance to fluconazole in Cryptococcus neoformans Cambodian isolates: April 2000 to March 2002. J Antimicrob Chemother 54 (2004) 563-565
7. Manfredi R., Fulgaro C., Sabbatani S., Legnani G., and Fasulo G. Emergence of amphotericin B-resistant Cryptococcus laurentii meningoencephalitis shortly after treatment for Cryptococcus neoformans meningitis in a patient with AIDS. AIDS Patient Care STDS 20 (2006) 227-232
8. Hancock R.E., and Patrzykat A. Clinical development of cationic antimicrobial peptides: from natural to novel antibiotics. Curr Drug Targets Infect Disord 2 (2002) 79-83
9. Zaiou M. Multifunctional antimicrobial peptides: therapeutic targets in several human diseases. J Mol Med 85 (2007) 317-329
10. Hirsch T., Jacobsen F., Steinau H.U., and Steinstraesser L. Host defense peptides and the new line of defence against multiresistant infections. Protein Pept Lett 15 (2008) 238-243
11. Hancock R.E., and Sahl H.G. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat Biotechnol 24 (2006) 1551-1557
12. Andrès E., and Dimarcq J.L. Clinical development of antimicrobial peptides. Int J Antimicrob Agents 25 (2005) 448-449
13. Rossi L.M., Rangasamy P., Zhang J., Qiu X.Q., and Wu G.Y. Research advances in the development of peptide antibiotics. J Pharm Sci 97 (2008) 1060-1070
14. Sang Y.M., and Blecha F. Antimicrobial peptides and bacteriocins: alternatives to traditional antibiotics. Anim Health Res Rev 9 (2008) 227-235
15. Cabras T., Longhi R., Secundo F., Nocca G., Conti S., Polonelli L., et al. Structural and functional characterization of the porcine proline-rich antifungal peptide SP-B isolated from salivary gland granules. J Pept Sci 14 (2008) 251-260
16. Benincasa M., Scocchi M., Pacor S., Tossi A., Nobili D., Basaglia G., et al. Fungicidal activity of five cathelicidin peptides against clinically isolated yeasts. J Antimicrob Chemother 58 (2006) 950-959
17. Torchilin V.P. Tat peptide-mediated intracellular delivery of pharmaceutical nanocarriers. Adv Drug Deliv Rev 60 (2008) 548-558
18. Rao K.S., and Labhasetwar V. Trans-activating transcriptional activator (TAT) peptide-mediated brain drug delivery. J Biomed Nanotechnol 2 (2006) 173-185
19. Liu L.H., Xu K.J., Wang H.Y., Tan P.K., Fan W., Venkatraman S.S., et al. Self-assembled cationic peptide nanoparticles as an efficient antimicrobial agent. Nat Nanotechnol 4 (2009) 457-463
20. Georgopapadakou N.H., and Walsh T.J. Antifungal agents: chemotherapeutic targets and immunologic strategies. Antimicrob Agents Chemother 40 (1996) 279-291
21. Luna T., Mazzolla R., Romanò G., and Blasi E. Potent antifungal effects of a new derivative of partricin A in a murine model of cerebral cryptococcosis. Antimicrob Agents Chemother 41 (1997) 706-708
22. Miller J.L., Schell W.A., Wills E.A., Toffaletti D.L., Boyce M., Benjamin Jr. D.K., et al. In vitro and in vivo efficacies of the new triazole albaconazole against Cryptococcus neoformans. Antimicrob Agents Chemother 48 (2004) 384-387
23. Perfect J.R., Cox G.M., Dodge R.K., and Schell W.A. In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans. Antimicrob Agents Chemother 40 (1996) 1910-1913
24. Kirkpatrick W.R., Najvar L.K., Bocanegra R., Patterson T.F., and Graybill J.R. New guinea pig model of Cryptococcal meningitis. Antimicrob Agents Chemother 51 (2007) 3011-3013
25. Wiegand I., Hilpert K., and Hancock R.E. Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances. Nat Protoc 3 (2008) 163-175
26. Sato H., and Feix J.B. Peptide-membrane interactions and mechanisms of membrane destruction by amphipathic α-helical antimicrobial peptides. Biochim Biophys Acta 1758 (2006) 1245-1256
27. Mason A.J., Bechinger B., and Kichler A. Rational design of vector and antibiotic peptides using solid-state NMR. Mini Rev Med Chem 7 (2007) 491-497
28. Bechinger B., and Lohner K. Detergent-like actions of linear amphipathic cationic antimicrobial peptides. Biochim Biophys Acta 1758 (2006) 1529-1539
29. Hancock R.E. Cationic peptides: effectors in innate immunity and novel antimicrobials. Lancet Infect Dis 1 (2001) 156-164
30. Oren Z., and Shai Y. Mode of action of linear amphipathic alpha-helical antimicrobial peptides. Biopolymers 47 (1998) 451-463
31. Boman H.G. Antibacterial peptides: basic facts and emerging concepts. J Intern Med 254 (2003) 197-215
32. Cho S., Wang Q., Swaminathan C.P., Hesek D., Lee M., Boons G.J., et al. Structural insights into the bactericidal mechanism of human peptidoglycan recognition proteins. Proc Natl Acad Sci USA 104 (2007) 8761-8766
33. Perfect J.R., Lang S.D., and Durack D.T. Chronic cryptococcal meningitis: a new experimental model in rabbits. Am J Pathol 101 (1980) 177-194
34. Perfect J.R., Wright K.A., Hobbs M.M., and Durack D.T. Treatment of experimental cryptococcal meningitis and disseminated candidiasis with SCH39304. Antimicrob Agents Chemother 33 (1989) 1735-1740